Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Dipal Doshi was last confirmed as Board Member at Entrada Therapeutics, Inc. (TRDA) in a filing dated April 25, 2025. The proxy statement of Entrada Therapeutics, Inc. reports total compensation of $3,837,737 for Dipal Doshi in fiscal 2025, including a base salary of $635,000. Disclosed compensation is on record for 5 fiscal years. Dipal Doshi has spoken on 1 earnings call across 1 company, most recently for Entrada Therapeutics, Inc. on May 7, 2026.
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2017-01-01–2025-04-25
Last confirmed by a filing; no departure on record
Recorded roles and call appearances connecting this person to public companies.
Board Member
Since 2017-01-01, last confirmed 2025-04-25
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Entrada Therapeutics, Inc. (TRDA) | Chief Executive Officer | $635,000 | $3,837,737 |
| 2024 | Entrada Therapeutics, Inc. (TRDA) | Chief Executive Officer | $610,000 | $3,891,503 |
| 2023 | Entrada Therapeutics, Inc. (TRDA) | Chief Executive Officer | $585,000 | $3,735,466 |
| 2022 | Entrada Therapeutics, Inc. (TRDA) | Chief Executive Officer | $565,000 | $3,491,063 |
| 2021 | Entrada Therapeutics, Inc. (TRDA) | President and Chief Executive Officer | $425,057 | $5,530,399 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
